表紙
市場調查報告書
商品編碼
987733

市場焦點:腫瘤崩壞症候群 (TLS)

Market Spotlight: Tumor Lysis Syndrome (TLS)

出版日期: | 出版商: Datamonitor Healthcare | 英文 28 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球高風險的惡性腫瘤(急性骨髓性白血病,急性淋巴性白血病,勃奇氏淋巴瘤)患者的腫瘤崩壞症候群 (TLS)的發病數量,2017年約12,400件,預計至2026年增加到13,600件。

本報告提供腫瘤崩壞症候群 (TLS) 調查分析,主要的上市藥,臨床試驗,成功的可能性,10年預測等相關的系統性資訊。

目錄

內容

概要

要點

疾病的背景

  • 亞型

治療

  • 預防和監測
  • 水分負擔
  • 醫學療法
  • 腎替代療法

流行病學

上市藥

成功的可能性

商機

臨床試驗形勢

  • 贊助商:各狀態
  • 贊助商:各階段

參考文件

附錄

目錄
Product Code: DMKC0183487

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma)

The number of incident cases is forecast to increase to 13,600 by 2026. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.

The overall likelihood of approval of a Phase I hematologic asset is 9.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TLS have been in the late phases of development, with 67% of trials in Phase III-IV, and 33% in Phase II.

The US leads in terms of the number of TLS clinical trials globally, while Italy and Spain lead the major European markets. Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with eight in total.

Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Prophylaxis and monitoring
  • Volume expansion
  • Medical therapies
  • Renal replacement therapy

EPIDEMIOLOGY

  • Incidence assumptions

MARKETED DRUGS

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017-26
  • Figure 2: Probability of success in the hematologic pipeline
  • Figure 3: Clinical trials in TLS
  • Figure 4: Top 10 drugs for clinical trials in TLS
  • Figure 5: Top 10 companies for clinical trials in TLS
  • Figure 6: Trial locations in TLS
  • Figure 7: TLS trials status
  • Figure 8: TLS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of TLS in selected high-risk malignancies, 2017-26
  • Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
  • Table 3: Incident cases of TLS in acute myeloid leukemia, 2017-26
  • Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
  • Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017-26
  • Table 6: Incidence of Burkitt's lymphoma, and proportion of individuals with TLS, 2017
  • Table 7: Incident cases of TLS in Burkitt's lymphoma, 2017-26
  • Table 8: Marketed drugs for TLS
  • Table 9: Historical global sales, by drug ($m), 2016-20
  • Table 10: Forecasted global sales, by drug ($m), 2021-25